- "Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for Persons Aged ≥18 Years at Risk for Mpox During an Mpox Outbreak: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023" published in MMWR
- Canada Day is July 1! Here’s a summary of vaccination information and advocacy in Canada.
- Confirmed measles cases increase to 1,214 across 34 states; encourage vaccination
- "Do I Need to Restart the PCV Series If a Child Started the Series with PCV13?” Watch the 1-minute synopsis, part of the Ask the Experts Video Series on YouTube
- Vaccines in the news
- Kaiser Family Foundation publishes an overview of how vaccine recommendations affect insurance coverage requirements
- Keep the 2025 immunization schedules at your fingertips! Order laminated 2025 U.S. immunization. schedule booklets from Immunize.org.
- Immunize.org's elegantly designed "Vaccines Save Lives" black enamel pins remind patients and families why we work so hard to prevent disease
CDC published Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for Persons Aged ≥18 Years at Risk for Mpox During an Mpox Outbreak: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023 on June 19 in MMWR. Portions of the article appear below.
CDC provides interim vaccination guidance for self-limited mpox outbreaks; however, a clade IIb outbreak that began in 2022 has had a protracted course, and the risk for U.S. mpox outbreaks has increased. . . .
On February 22, 2023, ACIP voted to recommend the 2-dose JYNNEOS vaccination series for persons aged ≥18 years who are considered to be at risk for mpox during an mpox outbreak. On October 25, 2023, ACIP voted to recommend the 2-dose JYNNEOS vaccination series for persons aged ≥18 years who are at risk for acquiring mpox during the ongoing clade IIb outbreak that began in 2022. For the latter vote, persons at risk included 1) MSM who, during the past 6 months, have had or anticipate experiencing at least one of the following: a new diagnosis of one or more sexually transmitted infections, more than one sex partner, sex at a commercial sex venue, or sex in association with a large public event in a geographic area where mpox transmission is occurring; 2) sexual partners of persons who have any of these risk factors; and 3) persons who anticipate experiencing any of these risk factors.
Access the MMWR article in HTML or PDF.
Related Links
- CDC: MMWR main page providing access to the MMWR family of publications
- Immunize.org: Vaccines A–Z: Mpox main page
O, Canada! Recognizing Canada’s 157th national anniversary on July 1, we share these select Canadian vaccination resources. Happy Canada Day to the vaccination providers and champions among our readers in Canada!
Expert committees:
- National Advisory Committee on Immunization (NACI), counterpart to ACIP
- Committee to Advise on Tropical Medicine and Travel (CATMAT)
Advocacy groups:
- CANVax (Canadian Vaccination Evidence Resource and Exchange Centre): search through their library of resources (curated by the Canadian Public Health Association)
- Immunize Canada: a national coalition of nongovernmental, professional, health, government, and private sector organizations with a specific interest in promoting the understanding and use of vaccines recommended by NACI
- Canadian Nurses Association
Helpful resources:
- Canadian Immunization Guide, counterpart to CDC’s "The Pink Book"
- Canadian Communicable Disease Report (CCDR), counterpart to MMWR
- Canadian Adverse Events following Immunization Surveillance System (CAEFISS)
- Public Health Agency of Canada (PHAC)
- Canadian Paediatric Society: Education Program for Immunization Competencies (EPIC)
- Provincial and Territorial Routine and Catch-Up Vaccination Schedule for Infants and Children in Canada
- Provincial and Territorial Routine Vaccination Programs for Healthy, Previously Immunized Adults
- Help Eliminate Pain in Kids & Adults: organization offering resources to make the vaccination experience more positive for everyone
- CARD System (Comfort, Ask, Relax, Distract): strategies that will help to provide a better vaccination experience
Government links:
- Health Canada, counterpart to HHS
- Public Health Agency of Canada (PHAC), counterpart to CDC
- Health Products and Food Branch (HPFB), counterpart to FDA
- Drug Product Database online query: list of drugs and vaccines permitted to be distributed within Canada, corresponding to licensed or approved status in the United States
As of June 19, CDC reported 1,214 confirmed measles cases in 2025 in 34 states. The states with the most confirmed cases in 2025 are Texas (750, 61.8%) and New Mexico (81, 6.7%). Among confirmed cases, 12% were hospitalized, with 21% younger than age 5 years.
CDC requires reporting of only laboratory-confirmed measles cases. Cases without laboratory testing for confirmation are not included in these numbers. Actual numbers of cases are, therefore, higher than confirmed case counts.
A map of 2025 measles cases in the contiguous United States, as of June 20, from the Johns Hopkins International Vaccine Access Center appears below. The U.S. Measles Tracker website includes state and county-level data.
Additionally, CDC offers resources for communities experiencing a measles outbreak, including infographics for families, images to help clinic personnel identify cases, guidance for caring for patients with measles, Travelers' Health: Global Measles web page, and a Be Ready for Measles communication toolkit. Spanish-language resources are now available on the toolkit page.
Related Links
- CDC: Measles Cases and Outbreaks main page
- CDC: Be Ready for Measles Toolkit
- Center for Outbreak Response Innovation: Measles Outbreak Response main page
- Immunize.org: Vaccines A–Z: Measles main page
- Immunize.org: Standing Orders for Administering Measles, Mumps, and Rubella Vaccine to Children and Teens (PDF)
- Immunize.org: Standing Orders for Administering Measles, Mumps, and Rubella Vaccine to Adults (PDF)
- Immunize.org: Ask the Experts: MMR (Measles, Mumps, and Rubella) web page
"Do I Need to Restart the PCV Series If a Child Started the Series with PCV13?” Watch the 1-minute synopsis, part of the Ask the Experts Video Series on YouTube
This week, our featured episode from the Ask the Experts Video Series is titled Do I Need to Restart the PCV Series If a Child Started the Series with PCV13? The video highlights that clinicians need not restart the vaccination series nor give additional doses. The previously administered doses of PCV 13 (Prevnar 13, Pfizer) are valid. The series may be completed with either PCV15 (Vaxneuvance, Merck) or PCV20 (Prevnar 20, Pfizer) according to the schedule.
The 1-minute video is available on our YouTube channel, along with our full collection of quick video answers to popular Ask the Experts questions.
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.
- Facebook at ImmunizeOrg
- Instagram at ImmunizeOrg
- LinkedIn at ImmunizeOrg
- YouTube at ImmunizeOrg
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
- STAT: Six Former CDC Vaccine Advisory Committee Chairs Warn: U.S. Risks Losing Access to Life-Saving Immunizations (6/20/25)
- West Virginia Watch: Health Groups Urge Insurers to Cover COVID-19 Shots for Pregnant Women (6/17/25)
- The Hill: RFK Jr.’s Vaccine Moves Raise Fears Ahead of Next School Year (6/16/25)
- The Hill: How Kennedy’s Overhaul Could Make Vaccines More Expensive (6/15/25)
- NPR: RFK Jr. Sent Congress ‘Medical Disinformation’ to Defend COVID Vaccine Schedule Change (6/13/25)
Immunize.org Website and Clinical Resources
Ask the Experts is one of the most visited sections of the Immunize.org website. With more than 1,300 entries, it provides practical and timely answers to your questions. You may explore five subsections: Ask the Experts Overview, View All Questions, View All Video Questions, Vaccine Topics, and General Topics.
In the example shown below, the reader is interested in the effectiveness of pertussis vaccine. After choosing “Pertussis” from the “Vaccine Topics,” one may click on “All Pertussis.” From there, one can narrow the search.
- Enter a word or phrase into “Keyword Search” (labeled #1 below). Alternatively, use the keyboard find command (Ctrl F). Either will produce yellow highlighted results to aid scanning across up to 65 hits per page.
- To show all highlighted results, click “Show All Answers.” This toggle button will become “Hide All Answers” when clicked again.
- To show highlighted results only in select questions, click the show/hide caret (⌄) on the far right (labeled #2)
- Apply filters to narrow results (“Show Filters” or “Hide Filters”)
When viewing Ask the Experts, there is now a link icon (🔗, labeled #3) on the right of each question banner, next to the show/hide caret (⌄). Selecting the link icon will copy the corresponding hyperlink for that one question and answer to your clipboard. A “link copied” message will briefly be displayed.
For additional support, view these resources from Immunize.org:
- Introducing Ask the Experts, video (3:36)
- Introducing Ask the Experts [Mobile View], video (3:36)
- Website Office Hours: Ask the Experts Website Section, webinar (32:35)
Featured Resources
On June 13, the Kaiser Family Foundation (KFF) published ACIP, CDC, and Insurance Coverage of Vaccines in the United States. This policy brief provides an overview of vaccine coverage requirements by insurance payer or program, considering vaccine recommendation changes made by the Trump Administration. The key findings can be summarized as follows:
- Almost all payers are required to cover recommended vaccines at no cost
- Vaccine coverage requirements are linked to ACIP/CDC recommendations in almost every case
- The point at which a vaccine is considered “recommended” for purposes of requiring no-cost coverage varies somewhat by payer, and in some cases was determined through subsequent rule-making or federal policy
- If ACIP or CDC vaccine recommendations were to be narrowed or removed, as recently done with COVID-19 vaccination, payers may choose to continue to provide no-cost coverage but would no longer be required to do so
Keep the 2025 immunization schedules at your fingertips! Order laminated 2025 U.S. immunization schedule booklets from Immunize.org.
Laminated booklets of the 2025 U.S. adult immunization schedule are available in the Immunize.org shop. The 2025 child and adolescent schedule booklets sold out.
The schedules are available online as PDFs from CDC at no cost. Immunize.org’s laminated booklets are ideal for use in any busy healthcare setting where vaccines are given.
Adult Booklets
1 copy: $10.00
2–4 copies: $9.50 each
5–19 copies: $8.50 each
20–99 copies: $7.50 each
100–499 copies: $6.00 each
500–999 copies: $5.00 each
1,000–1,999 copies: $4.00 each
2,000+ copies: $3.25 each
Visit the Shop Immunize.org: Laminated Schedules web page to view images and order today!
For additional information, call 651-647-9009 or email admininfo@immunize.org.
Related Links
- Immunize.org: Laminated Adult Immunization Schedules (19 and older) web page
- Immunize.org: Shop Immunize.org main page
Wear these pins on clothing, uniforms, and white coats to show that you value vaccines.
Click here for "Vaccines Save Lives" pin pricing and ordering information.
In the June 16 issue, JAMA published Advisory Committee on Immunization Practices at a Crossroads, an editorial written by the 17 former members of the ACIP. A portion of the editorial appears below.
ACIP committee members have always been selected through a rigorous process based on their expertise in immunology, epidemiology, pediatrics, obstetrics, internal and family medicine, geriatrics, infectious diseases, and public health. Historically, committee members were chosen because they worked at hospitals, clinics, health departments, universities, and other organizations where they dedicated themselves to caring for patients, conducting research, and helping to prevent and treat infectious diseases. Members’ deep understanding of immunization issues ensured that vaccine policies were grounded in scientific evidence, aligned with the needs of economically, socially, and medically diverse US communities, and always considered the public value, trust, and acceptability of vaccines.
CDC published Clade II Mpox Infections Among Cruise Ship Passengers and Crew Members—United States, 2024 on June 19 in MMWR. A portion of the summary appears below.
During the global clade II mpox outbreak, cases have disproportionately affected gay, bisexual, and other men who have sex with men (MSM). Cruise ship travel–associated mpox infections have not been previously described. . . .
During January 25–April 18, 2024, CDC was notified of eight mpox cases on four cruise ships: four among crew members and four among passengers. All cases occurred among MSM; five of eight patients had not been vaccinated against mpox. . . .
Cruise lines should consider educating crew members on symptoms, risks, and preventive measures related to mpox and working with medical personnel to facilitate mpox vaccination for eligible crew members. Cruise passengers who are recommended to get the vaccine should receive mpox vaccine before travel. For cruise voyages marketed to gay and bisexual men, mpox-prevention messaging and education before and during voyages are recommended.
Access the MMWR article in HTML or PDF.
Related Link
- CDC: MMWR main page providing access to the MMWR family of publications
CDC published Clade Ib Mpox Outbreak—Kenya, July 2024–February 2025 on June 19 in MMWR. A portion of the summary appears below.
Since July 2024, Kenya has been experiencing an mpox outbreak caused by clade Ib Monkeypox virus, a newly recognized subclade. . . .
Among 48 laboratory-confirmed clade Ib mpox cases diagnosed in Kenya during July 2024–February 2025, a total of 27 (56.3%) occurred among persons who worked as truck drivers, or were in contact with them, along a highway from Mombasa to Malaba, a transportation corridor that links Kenya to other East and Central African countries. Two thirds (30; 63%) of the cases were likely to have been sexually transmitted. Eleven (23%) patients also had HIV infection, one of whom died. . . .
Public health measures, including vaccination focusing on those most at risk for mpox such as truck drivers, sex workers, and persons traveling to countries with ongoing clade Ib mpox outbreaks, might help stop the spread of the disease within Kenya and to other countries.
Access the MMWR article in HTML or PDF.
Related Link
- CDC: MMWR main page providing access to the MMWR family of publications
CDC is scheduled to convene the ACIP on June 25–26 with a committee of 8 new voting members following the June 9 dismissal of all 17 voting members by the Department of Health and Human Services.
The meeting was originally scheduled as a 3-day meeting. A new, shorter agenda is planned. Recommendation votes are scheduled for RSV and influenza vaccines. Additionally, the agenda includes discussion of vaccines targeting anthrax, chikungunya, and COVID-19 diseases, as well as MMRV for children younger than age 5 years.
No registration is required to watch webcasts of live ACIP meetings or listen via telephone.
View meeting information.
View the agenda.
Related Links
- CDC: ACIP main page for access to webcast, agendas
- CDC: ACIP: Meeting Information for presentation slides, content from previous meetings, and information about future meetings
For more upcoming events, visit our Calendar of Events.